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SHORT COMMUNICATION
Is liver to lung shunting in colorectal liver metastasis the cause of toxicity
following treatment with cytotoxic microsphere aggregates?
T.W. Hennigan, S. Earlam & T.G. Allen-Mersh
Department ofSurgery, Charing Cross and Westminster Medical School, Fulham Palace Road, London W6 8RF, UK.
Summary Incorporation of cytotoxic drugs into microspheres reduces but does not eliminate systemic
toxicity. The extent of liver to lung shunt was measured in 26 patients with colorectal liver metastasis. Liver to
lung shunting correlated with proportion of liver replacement but did not exceed 4.4% and therefore is
unlikely to cause systemic toxicity.
Microspheres embolise in the first capillary bed encountered
and when given regionally into the hepatic artery do so in the
liver (Kerr et al., 1988). They may prolong tumour cytotoxic
exposure by two mechanisms. Firstly, they maybe contain the
cytotoxic agent and become trapped in the tumour and liver
vessels with leaching out of the cytotoxic into tumour (Codde
et al., 1990). Secondly, they may be administered at the same
time as the cytotoxic agent and thereby reduce drug washout
from the tumour capillary bed by reducing tumour blood
flow (Dahkil et al., 1982; Gyves et al., 1983).
Regional drug delivery using microspheres is also assoc-
iated with a reduction in systemic toxicity compared with
systemic delivery of cytotoxic agent alone (McArdle et al.,
1988). However, systemic toxicity including myelosuppression
still occurs (Codde et al., 1990; Anderson et al., 1989; Gold-
berg et al., 1990; Pfiefle et al., 1985). This may be due to
shunting of the microspheres through tumour-associated
arteriovenous communications of greater diameter than the
microspheres.
We have investigated the extent of this shunt in patients
with colorectal liver metastases and determined whether it is
related to extent of tumour liver replacement.
Methods
Patients studied
Twenty-six patients with colorectal liver metastases were
studied prior to treatment by hepatic artery infusion
chemotherapy using 5-fluorodeoxyuridine via a totally
implantable pump (Infusaid, Norwalk, Massachusetts).
Proportion liver volume replaced by tumour
An abdominal CT scan was performed within 3 weeks of the
study. All the CT scan slices (1 cm thick) in which the liver
appeared were studied. Th'e outline of the liver and of intra-
hepatic metastases on each slice were traced on transparent
paper. The transparency was projected onto a point grid. The
number of points lying within each metastasis and within
normal liver was counted. Liver and tumour point counts for
each slice were summed to give total liver area replacement.
This area replacement ratio is, by the Principle of Delesse
(Delesse, 1847; Grunwald & Wicher, 1985), equivalent to
ratio of volume replacement.
Following the CT scan an implantable infusion pump was
inserted with the infusion cannula placed in the gastro-
duodenal artery.
Proportion ofliver to lung shunting
Within 2 weeks of pump insertion, 5 mCi of technetium 99 m
labelled macroaggregated albumin stable for 6 h (20-40 ,sm
diameter, Pulmolyte, Du Pont, Stevenage) was injected via
the infusion pump side port directly into the gastroduodenal
artery.
A gamma camera scan (Scintronix gamma camera, 1 min
statis images) was performed and planar images obtained
2 min after 9Tc macroaggregated albumin administration
and a background correction made. Two regions of interest
were drawn on the images. The first around all of the liver
(Figure 2) and the second around both lungs (Figure 1).
Total lung counts were divided by the sum of liver counts to
derive a proportion of counts found in the lung compared
with the lung and liver counts.
Results
The median proportion of the liver area replaced (and
therefore, by the principle of Delesse, volume) was 19.5%
(interquartile range = 6 to 27%). The median proportion of
Figure 1 The bold line indicates the regions of interest encom-
passing the lungs with the liver visible below. In no case did the
ratio of lung:liver counts exceed 4.4%.
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Figure 2 The bold line indicates the region of interest
encompassing the liver with the infusion pump port visible at the
bottom left of the image.
liver to lung shunting was 1.3% (interquartile range 0.4% to
2.86%) and did not exceed 4.4%.
There was a weak but significant positive correlation
(r = 0.433, P= 0.027) between the proportion of liver to lung
shunt and the proportion of liver volume replaced.
Discussion
This study confirms that liver to lung shunting of micro-
spheres of a similar size to those used in treatment does
occur in human colorectal liver metastases. However, the
extent of the shunt was small and was always below 4.4% of
the counts retained in the tumour and liver despite extensive
liver replacement by tumour.
There was a correlation between the extent of the shunt
and the proportion of liver replacement by tumour. This
suggests that the shunt was associated with tumour. It may
be that the shunt was via vessels greater than 20tim diameter
situated in and around the tumour. Alternatively, the tumour
could affect the normal liver vasculature by increasing the
diameter of the normal liver vessels to allow the passage of
the microaggregates.
Since the extent of the shunting which was identified was
small, it is unlikely that this could be the reason for the
toxicity associated with microsphere treatment. Therefore,
attempts to diminish systemic toxicity by using larger micro-
spheres which would not pass through the shunt is unlikely
to be effective in reducing toxicity. Toxicity with cytotoxic-
containing microspheres is more likely to be due to the
release of cytotoxic drug from the microspheres into the
systemic circulation after administration.
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